Ignite Creation Date:
2025-12-24 @ 7:09 PM
Ignite Modification Date:
2026-02-25 @ 4:57 PM
Study NCT ID:
NCT02450903
Status:
COMPLETED
Last Update Posted:
2021-03-30
First Post:
2015-05-08
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Sponsor:
Novartis Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CLDK378A1201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None